ERT eCOA Solution Assists in Migraine Study
ERT eCOA diaries and solution delivery enable CoLucid Pharmaceuticals to collect quality data, on time, while minimizing study complexity and risk
PHILADELPHIA, PA –
ERT
, a leading provider of high-quality patient data collection solutions for use in clinical drug development, today announced that its electronic Clinical Outcome Assessment (eCOA) diaries and expert solution delivery enabled CoLucid Pharmaceuticals to achieve the primary and key secondary efficacy endpoints in its
Phase 3 SAMURAI study of lasmiditan
in adults with migraine. During the pivotal trial, patients used ERT’s electronic diary (eDiary) to record migraine occurrence and to rate headache pain severity as well as presence of the most bothersome symptom, including nausea, phonophobia or photophobia. Patients then used ERT’s eDiary at protocol-defined times post-dose to assess the degree of headache pain and the presence or absence of each associated symptom. “ERT was able to design eDiaries that were easy enough for this affected patient population to complete while they were suffering from migraine symptoms,” said Bernice Kuca, Head Clinical and Regulatory Operations, CoLucid. “We are pleased with their implementation of the eDiary solution, which enabled us to maintain study timelines, as well as the critical endpoint data they delivered in support of our program.” Ron Sullivan, Executive Vice President and Product Line Executive for eCOA noted “We’re honored that CoLucid relied on our eCOA system and expertise to capture this important efficacy data.” For more information on ERT’s eCOA system, visit
https://www.ert.com/ecoa
About ERT
ERT is a leading provider of high-quality patient data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process. ERT delivers widely deployed solutions in centralized Cardiac Safety, Respiratory, and electronic Clinical Outcome Assessments (eCOA) – which includes patient-, clinician-, observer- and performance-reported outcomes – and cloud-based analytics and performance metrics. By efficiently integrating these solutions through a system built upon a scientific and regulatory foundation, ERT collects, analyzes and delivers safety and efficacy data critical to the approval, labeling and reimbursement of pharmaceutical products. For more information see
www.ert.com
. Join ERT on
,
,
YouTube
and
.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.
